modelZidovudineAndLamivudine
Extends from Pharmacolibrary.Drugs.ATC.J.J05AR01.
Information
| name: | ZidovudineAndLamivudine | |
| ATC code: | J05AR01 | route: | oral |
| compartments: | 1 | |
| dosage: | 300 | mg |
| volume of distribution: | 1.6 | L |
| clearance: | 1.6 | L/h/kg |
| other parameters in model implementation | ||
Zidovudine and lamivudine are antiretroviral medications combined to treat HIV-1 infection. Both are nucleoside reverse transcriptase inhibitors (NRTIs) and are used as a backbone in combination antiretroviral therapy (ART). The fixed-dose combination is approved and widely used today for the management of HIV infection.
Pharmacokinetics
Pharmacokinetic parameters for zidovudine and lamivudine following oral administration in healthy adult volunteers.
References
Zhou, XJ, et al., & Sommadossi, JP (2000). Plasma population pharmacokinetics and penetration into cerebrospinal fluid of indinavir in combination with zidovudine and lamivudine in HIV-1-infected patients. AIDS (London, England) 14(18) 2869–2876. DOI:10.1097/00002030-200012220-00008 PUBMED:https://pubmed.ncbi.nlm.nih.gov/11153668
Anderson, PL, et al., & Fletcher, CV (2006). Pharmacogenetic characteristics of indinavir, zidovudine, and lamivudine therapy in HIV-infected adults: a pilot study. Journal of acquired immune deficiency syndromes (1999) 42(4) 441–449. DOI:10.1097/01.qai.0000225013.53568.69 PUBMED:https://pubmed.ncbi.nlm.nih.gov/16791115
Bhana, N, et al., & Figgitt, DP (2002). Zidovudine: a review of its use in the management of vertically-acquired pediatric HIV infection. Paediatric drugs 4(8) 515–553. DOI:10.2165/00128072-200204080-00004 PUBMED:https://pubmed.ncbi.nlm.nih.gov/12126455
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)